Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Immune Response After Pancreatic Cancer Treatment (IRE Immuno)

25. februar 2020 opdateret af: University Hospital Inselspital, Berne

Differential Immunologic Signature After Pancreatic Cancer Treatment: Does Irreversible Electroporation Lead to a Prolonged and Potent T-cell Mediated Immune Response Compared to Surgical Resection?

The aim of this project is to describe the differential immunologic responses of patients who undergo in situ IRE, margin accentuation IRE with surgical resection of the primary tumor, and surgical resection of the primary tumor only. The primary hypothesis is that IRE induces a long and sustained activation of the cell-mediated immune system, which is distinct from the immune response after surgical resection only. The primary endpoint of this study is the comparison of the CD4+/CD8+ ratio as an indicator of antitumor immunity both longitudinally within a group after the intervention and over time between the three groups. CD4+/CD8+ ratio will be measured preoperatively and at postoperative days 1, 7, 42, and 180. As a secondary outcome, additional measurements will be taken to more specifically characterize the immune response based on peripheral blood samples. Flow cytometry will be used to quantify cell subsets, and ELISA will be used to measure cytokine levels , at the same time-points as for the primary outcome. Each group of patients as described above will consist of 10 consecutive pancreatic cancer patients. Patients aged 18 or older with resectable, borderline resectable, or locally advanced pancreatic cancer will be included. Patients with locally advanced disease will undergo 3 months of preoperative chemotherapy with monitoring to exclude metastatic disease. Main exclusion criteria are cardiac conduction abnormalities and signs of distant metastasis.

Studieoversigt

Status

Afsluttet

Betingelser

Intervention / Behandling

Undersøgelsestype

Observationel

Tilmelding (Faktiske)

38

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

  • Schweiz
      • Bern, Schweiz
        • Inselhospital

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Prøveudtagningsmetode

Ikke-sandsynlighedsprøve

Studiebefolkning

Patients undergoing an established procedure for pancreatic cancer. The assignment into either group will be independent of this research proposal and rely completely on clinical judgment. Main outcomes will be changes in immunological short-term and long-term outcomes.

Beskrivelse

Inclusion Criteria:

  • Age ≥ 18 years
  • Able to undergo general anesthesia (ASA ≤ 4)
  • Performance status ECOG <=2 (Eastern Cooperative Oncology Group)
  • Life expectancy of at least 6 months
  • Resectable, borderline resectable, or locally advanced pancreatic cancer
  • Patients who have locally advanced disease have to show no tumor progression after 3 month of neo-adjuvant chemotherapy+/-XRT before undergoing in situ IRE

Exclusion Criteria:

  • Cardiac AV conduction abnormalities, ventricular fibrillation
  • History of epilepsy
  • Recent history of myocardial infarction (2 months)
  • Evidence of distant metastasis (e.g. liver, lung, peritoneum)
  • Informed consent cannot be given by the patient
  • Known hypersensitivity to the IRE electrodes (stainless steel 304L)
  • Women of childbearing potential who are pregnant, breast feeding, or not taking an adequate method of contraception at the time of procedure

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

Kohorter og interventioner

Gruppe / kohorte
Intervention / Behandling
10 IRE locally advanced
patients undergoing in situ IRE for locally advanced pancreatic
Procedure: irreversible electroporation (IRE)
Irreversible electroporation is an emerging, mainly non-thermal ablative modality. It circumvents some downsides of thermal ablation and has the potential for broad application among patients with pancreatic cancer.
10 IRE borderline resection
patients undergoing margin accentuation IRE for borderline resectable disease
Procedure: irreversible electroporation (IRE)
Irreversible electroporation is an emerging, mainly non-thermal ablative modality. It circumvents some downsides of thermal ablation and has the potential for broad application among patients with pancreatic cancer.
10 resection only
patients undergoing surgical resection only

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Immunological outcome
Tidsramme: 42 days
flowcytometry
42 days
Immunological outcome
Tidsramme: 6 months
Flowcytometry
6 months
Immunological outcome
Tidsramme: 9 months
Flowcytometry
9 months
Immunological outcome
Tidsramme: 42 days
ELISA
42 days
Immunological outcome
Tidsramme: 6 months
ELISA
6 months
Immunological outcome
Tidsramme: 9 months
ELISA
9 months

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Number of local tumor recurrences
Tidsramme: 42 days
measured via CT
42 days
Number of local tumor recurrences
Tidsramme: 3 months
measured via CT
3 months
Number of local tumor recurrences
Tidsramme: 6 months
measured via CT
6 months
Number of local tumor recurrences
Tidsramme: 9 months
measured via CT
9 months
Number of distant tumor recurrences
Tidsramme: 42 days
measured via CT
42 days
Number of distant tumor recurrences
Tidsramme: 3 months
measured via CT
3 months
Number of distant tumor recurrences
Tidsramme: 6 months
measured via CT
6 months
Number of distant tumor recurrences
Tidsramme: 9 months
measured via CT
9 months
Overall survival
Tidsramme: 42 days
survival of patient
42 days
Overall survival
Tidsramme: 3 months
survival of patient
3 months
Overall survival
Tidsramme: 6 months
survival of patient
6 months
Overall survival
Tidsramme: 9 months
survival of patient
9 months
Cancer specific survival
Tidsramme: 42 days
survival of patient
42 days
Cancer specific survival
Tidsramme: 3 months
survival of patient
3 months
Cancer specific survival
Tidsramme: 6 months
survival of patient
6 months
Cancer specific survival
Tidsramme: 9 months
survival of patient
9 months

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

University Hospital Inselspital, Berne

Efterforskere

  • Ledende efterforsker: Mathias Worni, MD, Inselspital Berne

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

15. februar 2017

Primær færdiggørelse (Faktiske)

25. februar 2020

Studieafslutning (Faktiske)

25. februar 2020

Datoer for studieregistrering

Først indsendt

20. december 2016

Først indsendt, der opfyldte QC-kriterier

2. marts 2017

Først opslået (Faktiske)

3. marts 2017

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

26. februar 2020

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

25. februar 2020

Sidst verificeret

1. februar 2020

Mere information

Begreber relateret til denne undersøgelse

Yderligere relevante MeSH-vilkår

Andre undersøgelses-id-numre

  • 2016-02037

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Kliniske forsøg med Kræft i bugspytkirtlen

Kliniske forsøg med irreversible electroporation (IRE)

Søg i lignende forsøg

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

CROs by country

CROs in Japan

Betingelser

Sjældne sygdomme

Narkotikainterventioner

Kosttilskud

Sponsor / samarbejdspartnere

Placeringer

Abonner